Diabetes

A target trial emulation found GLP-1 RA initiation was associated with a 21% lower 3-year fragility fracture risk compared with DPP-4 inhibitor therapy.

Use of automated insulin delivery technology improves a Healthcare Effectiveness Data and Information Set quality measure in individuals with type 2 diabetes.

Findings from CRISPR-edited stem cell–derived islets suggest SMOC1 functions as a physiological stabilizer of NKX6.1-positive β-cell identity.

Two studies identify molecular targets that could help preserve insulin-producing cell function.

Adults treated with insulin showed sustained A1C improvements and fewer acute care visits among patients whose CGM was initiated in primary care compared with similar patients who did not initiate CGM.

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.

Resistance training, especially when paired with aerobic activity and limited TV time, was associated with the steepest reductions in type 2 diabetes risk.

An 18-month Illinois pilot linking prison clinicians to endocrinologists via telehealth achieved a mean HbA1c reduction of 1.6 percentage points across 115 incarcerated men with diabetes.

ADA 2026 spotlighted triple incretin therapy, intensive LDL lowering, and the equity gaps that keep advances from reaching all patients.

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages.

Orforglipron added to titrated insulin glargine reduced HbA1c at 40 weeks while producing clinically meaningful weight reductions.

The authors evaluated changes in persistence to basal insulin in a Medicare Advantage population in the first year of the Medicare insulin out-of-pocket cost cap.

Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve medication-taking behavior.

High-dose vitamin D₃ supplementation reduced diabetes risk by 19% in adults with prediabetes who carry specific vitamin D receptor gene variants.

Shara Bialo, MD, emphasizes the crucial role of school nurses in early detection of type 1 diabetes.

This study found high out-of-pocket costs for branded diabetes medications in employer-sponsored health plans.

Teplizumab-mzwv is the first disease-modifying therapy available for children as young as 1 year diagnosed with presymptomatic type 1 diabetes.

Receipt of an insurer-provided grocery benefit was associated with decreased rates of diabetes with complications and increased medication adherence among a population with diabetes.

The 2026 Regional Diabetes Summit is taking place from April 28 to 29, 2026, in Wilmington, Delaware.

The FDA has approved the first generic versions of dapagliflozin, expanding access to a widely used SGLT2 inhibitor.

The cap cut quarterly spending by the hundreds and lowered A1c levels but failed to expand the pool of insulin users.

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries.

Findings show sustained reductions in HbA1c, weight, blood pressure, inflammation, and lipids in patients with T2D and ASCVD or CKD.